NIAID Program staff has indicated that proposals submitted on or after April 2025 will be considered for funding in Fiscal Year 2027
However, the absence of a direct interaction does not guarantee optimal outcomes
Discussion In this study, we have demonstrated for the first time that inhibition of both the ligand and the receptor of the HGF/c-MET pathway (using a neutralising antibody against HGF and a small-molecule c-MET receptor inhibitor) in combination with a chemotherapeutic agent (gemcitabine), that is, (triple therapy, Hi + Ci + G) significantly reduced tumour size and, more importantly, completely eradicated metastasis in a clinically relevant advanced pancreatic cancer model
its like crude oil that needs to be refined
IBS, irritable bowel syndrome ROS, reactive oxygen species
The PlexusDx Precision Peptide Genetic Test reveals these predispositions, allowing your provider to weigh whether GLP-1 therapy, compounded tirzepatide dual-receptor activation, or alternative strategies align better with your biology and surgical history